title: Zoledronic Acid Dosing Interval for Metastatic Cancer-Reply.
authors.affiliation: Helen F. Graham Cancer Center and Research Institute, Newark, Delaware.
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Himelstein
authors.affiliation: Mayo Clinic, Rochester, Minnesota.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
authors.affiliation: Icahn School of Medicine at Mount Sinai, New York, New York.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Shapiro
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D050071:Bone Density Conservation Agents; D007093:Imidazoles